Literature DB >> 35562625

Thyroid receptor β might be responsible for breast cancer associated with Hashimoto's thyroiditis: a new insight into pathogenesis.

Muskaan Dhingra1, Shayon Mahalanobis1, Asmita Das2.   

Abstract

Breast cancer is the most common cancer affecting females worldwide. Often it is observed that women suffering from Hashimoto's thyroiditis exhibit a greater propensity towards development of breast cancer. The exact mechanism for the same is unknown. However, multiple experimental evidences suggest a significant role of thyroid receptor β (TR-β) in regulating cell growth and proliferation and thus play a potent role as a tumor suppressor in several cancers, including breast cancer. Thyroid receptor β shows anti-proliferative action through mediators like β-catenin, RUNX2, PI3K/AKT, and cyclin regulation. The present review explores the link between these pathways and how they may be dysregulated due to Hashimoto's thyroiditis. Further, we propose a new mechanism for cancer prognosis associated with Hashimoto's thyroiditis, which may lead to the development of TR-β targeting as a novel therapeutic approach.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Autoimmune disorder; Breast cancer; Cancer therapeutics; Hashimoto’s thyroiditis; Thyroid receptor β

Mesh:

Year:  2022        PMID: 35562625     DOI: 10.1007/s12026-022-09288-7

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   4.505


  33 in total

1.  Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Cancer Res       Date:  2020-06-17       Impact factor: 5.852

2.  Thyroid hormone receptor-beta (TR beta 1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2.

Authors:  E Porlan; O G Vidaurre; A Rodríguez-Peña
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

Review 3.  Hypothyroidism.

Authors:  Layal Chaker; Antonio C Bianco; Jacqueline Jonklaas; Robin P Peeters
Journal:  Lancet       Date:  2017-03-20       Impact factor: 79.321

Review 4.  Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation.

Authors:  Massimo Ralli; Diletta Angeletti; Marco Fiore; Vittorio D'Aguanno; Alessandro Lambiase; Marco Artico; Marco de Vincentiis; Antonio Greco
Journal:  Autoimmun Rev       Date:  2020-08-15       Impact factor: 9.754

Review 5.  Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy.

Authors:  Francesca Ragusa; Poupak Fallahi; Giusy Elia; Debora Gonnella; Sabrina Rosaria Paparo; Claudia Giusti; Leonid P Churilov; Silvia Martina Ferrari; Alessandro Antonelli
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2019-11-26       Impact factor: 4.690

6.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.

Authors:  Fumihiko Furuya; John A Hanover; Sheue-yann Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

Review 7.  Hashimoto thyroiditis: clinical and diagnostic criteria.

Authors:  P Caturegli; A De Remigis; N R Rose
Journal:  Autoimmun Rev       Date:  2014-01-13       Impact factor: 9.754

8.  A 2011 survey of clinical practice patterns in the management of Graves' disease.

Authors:  Henry B Burch; Kenneth D Burman; David S Cooper
Journal:  J Clin Endocrinol Metab       Date:  2012-10-05       Impact factor: 5.958

Review 9.  Management of Graves Disease: A Review.

Authors:  Henry B Burch; David S Cooper
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272

Review 10.  Treatment for primary hypothyroidism: current approaches and future possibilities.

Authors:  Ali J Chakera; Simon H S Pearce; Bijay Vaidya
Journal:  Drug Des Devel Ther       Date:  2011-12-22       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.